Trial Profile
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSV¿G-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Lambaréné, Gabon.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2020
Price :
$35
*
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 01 Oct 2017 Results published in the PLOS Medicine.
- 01 Apr 2015 Status changed from planning to recruiting, as reported in a Public Health Agency of Canada media release.
- 02 Dec 2014 New trial record